Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026)
Vireo Growth (VREOF) reported Total Non-Current Liabilities of $604.7 million for Q1 2026, up 166.89% on a YoY basis from $226.6 million in Q1 2025, and up 19.08% sequentially from $507.8 million in Q4 2025.
Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 6 years of Total Non-Current Liabilities data on file, last reported at $604.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 166.89% year-over-year to $604.7 million; the trailing twelve-month figure through Mar 2026 stood at $604.7 million (up 166.89% YoY), and the FY2025 full-year result was $507.8 million, up 127.41% from the prior year.
- Total Non-Current Liabilities rose to $604.7 million in Q1 2026, from $507.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $604.7 million in Q1 2026 to a low of $155.7 million in Q4 2022.
- A 5-year average of $286.3 million and a median of $217.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities gained 6.14% in 2025 and surged 166.89% in 2026, its largest moves.
- Tracing VREOF's Total Non-Current Liabilities over 5 years: stood at $155.7 million in 2022, then gained by 27.92% to $199.2 million in 2023, then climbed by 12.11% to $223.3 million in 2024, then surged by 127.41% to $507.8 million in 2025, then climbed by 19.08% to $604.7 million in 2026.
- Business Quant data shows VREOF's Total Non-Current Liabilities at $604.7 million in Q1 2026, $507.8 million in Q4 2025, and $431.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 604.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 604.70 Mn |
| Dec 31, 2025 | 507.80 Mn |
| Sep 30, 2025 | 431.51 Mn |
| Jun 30, 2025 | 380.13 Mn |
| Mar 31, 2025 | 226.57 Mn |
| Dec 31, 2024 | 223.30 Mn |
| Sep 30, 2024 | 204.66 Mn |
| Jun 30, 2024 | 217.04 Mn |
| Mar 31, 2024 | 213.46 Mn |
| Dec 31, 2023 | 199.19 Mn |
| Sep 30, 2023 | 184.29 Mn |
| Jun 30, 2023 | 173.66 Mn |
| Dec 31, 2022 | 155.71 Mn |
| Sep 30, 2021 | 110.17 Mn |
| Jun 30, 2021 | 52.73 Mn |
| Mar 31, 2021 | 58.01 Mn |